EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+1.88%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$6.75B
AUM Growth
+$6.75B
(+4.6%)
Cap. Flow
+$463M
Cap. Flow
% of AUM
6.86%
Top 10 Holdings %
Top 10 Hldgs %
24.03%
Holding
179
New
20
Increased
67
Reduced
21
Closed
18
Top Buys
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$65.6M |
| 2 |
Entegris
ENTG
|
$60.2M |
| 3 |
TSMC
TSM
|
$50.5M |
| 4 |
Cullinan Oncology
CGEM
|
$49M |
| 5 |
Zymeworks
ZYME
|
$44.1M |
Top Sells
| 1 |
Ecolab
ECL
|
$49.8M |
| 2 |
Wayfair
W
|
$49M |
| 3 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
$41.8M |
| 4 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$23.8M |
| 5 |
CrowdStrike
CRWD
|
$20.3M |
Sector Composition
| 1 | Healthcare | 40.17% |
| 2 | Technology | 26.2% |
| 3 | Industrials | 11.22% |
| 4 | Consumer Discretionary | 7.43% |
| 5 | Communication Services | 4.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pool Corp
POOL
$11.4B
| $86.4M | 1.28% |
250,200
-1,600
| -0.6% | -$552K |
|
27
Cintas
CTAS
$82.9B
| $83.3M | 1.24% |
244,200
+65,200
| +36% | +$22.3M |
|
|
TRIL
28
DELISTED
Trillium Therapeutics Inc.
TRIL
| $82.3M | 1.22% |
7,659,000
+2,877,552
| +60% | +$30.9M |
|
29
Trex
TREX
$6.41B
| $80.7M | 1.2% |
882,000
| – | – |
|
|
30
Wayfair
W
$10.3B
| $77.6M | 1.15% |
246,432
-155,568
| -39% | -$49M |
|
31
Verisk Analytics
VRSK
$37.5B
| $75.1M | 1.11% |
424,800
+5,500
| +1% | +$972K |
|
32
Generac Holdings
GNRC
$10.3B
| $75.1M | 1.11% |
229,200
+86,200
| +60% | +$28.2M |
|
33
Magna International
MGA
$12.7B
| $74.7M | 1.11% |
848,000
+44,700
| +6% | +$3.94M |
|
34
Aptiv
APTV
$17.3B
| $74.1M | 1.1% |
537,000
| – | – |
|
35
ESSA Pharma
EPIX
$11.2M
| $69.9M | 1.04% |
2,405,169
+70,000
| +3% | +$2.03M |
|
|
36
Entegris
ENTG
$12B
| $68.9M | 1.02% |
616,099
+538,470
| +694% | +$60.2M |
|
37
RingCentral
RNG
$2.74B
| $65.9M | 0.98% |
221,108
+5,210
| +2% | +$1.55M |
|
38
Vital Farms
VITL
$2.2B
| $65.7M | 0.97% |
3,008,232
+955,000
| +47% | +$20.9M |
|
|
RXDX
39
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $65.6M | 0.97% |
+3,714,032
| New | +$65.6M |
|
40
argenx
ARGX
$44.2B
| $58.9M | 0.87% |
214,000
+54,000
| +34% | +$14.9M |
|
41
Sprout Social
SPT
$896M
| $58.4M | 0.87% |
1,010,920
-4,000
| -0.4% | -$231K |
|
42
Collegium Pharmaceutical
COLL
$1.25B
| $57.5M | 0.85% |
2,427,976
| – | – |
|
43
Annexon
ANNX
$225M
| $54.7M | 0.81% |
2,004,616
| – | – |
|
44
Crown Castle
CCI
$42.3B
| $54M | 0.8% |
314,000
+36,600
| +13% | +$6.3M |
|
45
Sutro Biopharma
STRO
$85.6M
| $54M | 0.8% |
2,370,975
| – | – |
|
|
46
TSMC
TSM
$1.2T
| $53.6M | 0.79% |
453,100
+427,300
| +1,656% | +$50.5M |
|
47
Brookfield Renewable
BEP
$7B
| $52.7M | 0.78% |
1,236,000
| – | – |
|
48
Sarepta Therapeutics
SRPT
$1.98B
| $52M | 0.77% |
697,156
-234,356
| -25% | -$17.5M |
|
49
Yeti Holdings
YETI
$2.84B
| $49.8M | 0.74% |
690,000
| – | – |
|
|
50
Cullinan Oncology
CGEM
$456M
| $49M | 0.73% |
+1,212,555
| New | +$49M |
|